Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.73 |
| ▸ | CLK1 | P49759 | 2/20 | 0.70 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.70 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.70 |
| ▸ | KIT | P10721 | 7/20 | 0.70 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.67 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.66 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763545 | 0.92 | DYRK1A (0.80) | DYRK1AKITAAK1SLC2A1MAP3K11 | |
| SCHEMBL1516821 | 0.91 | KIT (0.70) | DYRK1AKITAAK1SLC2A1MAP3K11 | |
| SCHEMBL1516586 | 0.86 | AAK1 (0.65) | DYRK1AKITAAK1SLC2A1MAP3K11 | |
| SCHEMBL15833808 | 0.85 | DYRK1A (1.00) | DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3770371 | 0.83 | DYRK1A (1.00) | DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL7111627 | 0.83 | KIT (0.61) | DYRK1AKITAAK1SLC2A1MAP3K11 | |
| SCHEMBL15833894 | 0.82 | KIT (1.00) | DYRK1AKITAAK1SLC2A1 | |
| SCHEMBL1516600 | 0.82 | KIT (0.83) | DYRK1AKITAAK1SLC2A1 | |
| SCHEMBL12763546 | 0.82 | AAK1 (0.59) | DYRK1AKITAAK1SLC2A1 | |
| SCHEMBL15833765 | 0.81 | KIT (0.70) | DYRK1ACLK1DYRK2DYRK1BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906648-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906648-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2264033-A1 | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS | SGX Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-7601839-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601839-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7582637-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | DYRK1A 261/4885CLK1 422/4885DYRK2 227/4885 |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | DYRK1A 261/4885CLK1 422/4885DYRK2 227/4885 |
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | DYRK1A 261/4885CLK1 422/4885DYRK2 227/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | DYRK1A 673/4885CLK1 515/4885DYRK2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.